New drug trial targets debilitating itch in liver disease patients

NCT ID NCT06733519

Summary

This study is testing whether an investigational drug called TH104 can safely reduce severe itching in people with primary biliary cholangitis (PBC), a chronic liver disease. Forty participants with moderate to severe itching will receive either TH104 or a placebo for six weeks, followed by two weeks of monitoring. The main goal is to check the drug's safety while also measuring its effect on itch intensity and quality of life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY BILIARY CHOLANGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.